Tata Chemicals — four quarters of waiting for the soda ash cycle to turn

The State of Play

Tata Chemicals ended FY26 with a ₹1,715 crore consolidated loss — its India business actually grew and stayed profitable, but a ₹1,837 crore writedown on its American soda ash operation, plus a year of prices “approaching record low levels,” sank the group. The stock trades below book value, the P/E column on screener is simply blank, and the year’s four earnings calls trace a steady retreat: a ₹600 crore improvement target trimmed to 75%, a UK turnaround that slipped six months, a US expansion shelved “until the cycle returns,” and all new money pointed at India. The CEO’s own closing words in May: “It’s been a difficult quarter and a difficult operating environment.”

The Company

Tata Chemicals is, at its core, a soda ash company — the world’s third-largest producer of a white powder that goes into glass, detergents and, increasingly, solar panels and lithium processing. Its edge is geology: more than two-thirds of its output is natural soda ash, mined from trona deposits in Wyoming and Lake Magadi in Kenya, which is structurally cheaper to make than the synthetic kind cooked up in chemical plants (most of China’s capacity). Around that core sit salt (sold to sister company Tata Consumer), sodium bicarbonate, specialty silica, food ingredients (FOS), and the listed agrochemicals subsidiary Rallis India. Operations span Gujarat (Mithapur), Wyoming, the UK (Northwich) and Kenya.

Promoters — Tata Sons — hold a steady 37.98%. Over the past three years FIIs have drifted out (14.47% → 11.90%) while domestic institutions accumulated (19.91% → 22.83%). Market cap is ₹18,308 crore against a book value that works out to 0.86x — the market pricing in that the book may not be worth the book.

The annual reports chart the descent. FY24: profit from continuing operations collapsed 82% to ₹449 crore as the soda ash cycle broke — the basic chemistry segment’s result fell from ₹3,028 crore to ₹955 crore in one year. FY25: revenue slipped another 3.5% to ₹14,887 crore, consolidated PAT down to ₹387 crore. FY26: a swing to the ₹1,715 crore loss — with the telling footnote that India standalone grew revenue 8.8% and earned ₹606 crore. The entire damage sits overseas.

The Story So Far

July 2025 — Q1 FY26: “prices have more or less bottomed out”

The year began on a deceptively firm note: consolidated revenue of ₹3,719 crore, EBITDA of ₹649 crore, PAT of ₹316 crore — though ₹75 crore of that was an old income-tax refund, which the CFO flagged himself. MD & CEO R. Mukundan reaffirmed the year’s central promise, a ~₹600 crore structural EBITDA improvement built from three ₹200 crore blocks: shutting the unviable Lostock soda ash plant in the UK, new capacity ramping in India and Kenya, and cost-outs.

“U.K. is more or less in the bag. I think in terms of expansion also more or less in the bag. I think the cost out is work-in-progress.” — R. Mukundan, MD & CEO

The market read was patient-bullish: demand “is actually very fine… Our issue is more from the excess supply,” prices “have more or less bottomed out,” expected flat for six to nine months. The capex story was the cleanest commitment of the year: the peak cycle was over — FY26 would be ~₹1,000 crore of maintenance spend, “everything is done last year.” The 4-lakh-ton US expansion was explicitly paused “for a couple of quarters or maybe a year.” Analysts noticed what wasn’t said: the CFO declined a US steady-state EBITDA run-rate, the current export share, and the full-year tax rate, and Kotak’s Abhijit Akella pointed out the company had quietly dropped its US volume disclosure. (“Noted,” said the CFO.)

November 2025 — Q2 FY26: the target gets a haircut

India delivered — standalone revenue up 19%, EBITDA up 67%, PAT up 80%, on volumes rather than price. But the consolidated picture cracked: revenue down 3% to ₹3,877 crore, EBITDA down to ₹537 crore from ₹618 crore, with ~₹105 crore of one-offs (a ₹65 crore UK cessation provision, a ~$5 million US fixed-cost under-absorption). The US quarter was the shock — EBITDA fell from ₹188 crore to ₹77 crore sequentially, with management guiding the normalized base down to “about ₹55-odd crores… at the current pricing.”

Under direct questioning from Morgan Stanley’s Vivek Rajamani, the ₹600 crore promise from July got its haircut:

“Instead of Rs. 600 crores, we would say that we should be there about 75% of the numbers.” — R. Mukundan

The UK got a fresh deadline — “we do expect to turn positive in the 3rd quarter of this year and definitely moving to positive by 4th quarter” — and the industry data stayed grim: Chinese prices down 56–58% in three years, most Chinese production at negative cash margin, China’s inventory pile at 1.65 million tonnes. The call’s real purpose, though, was teeing up a pivot: a ~50% expansion of Indian soda ash capacity (150,000 tonnes quickly, 350,000 staged), new silica lines, FOS doubling — funded by ₹1,500 crore of NCDs, with full plans promised at Q3. Four months after “peak capex is over,” the company was raising debt to grow. The destination had changed: India, not Wyoming.

February 2026 — Q3 FY26: into the red

The third quarter swung to a consolidated loss — PAT before exceptionals of negative ₹15 crore against +₹49 crore a year earlier, EBITDA down 20% to ₹345 crore, “mainly on account of subdued pricing across all geographies,” with the US the sharpest drag. (India standalone, again, grew: EBITDA up 9%, PAT up 21%.) The promised India plans materialized as three board approvals: a ₹515 crore greenfield iodized salt plant at Valinokkam in Tamil Nadu (210 KTPA), a ₹775 crore silica expansion at Cuddalore (50 KTPA), and — the clever one — a ₹135 crore dense soda ash plant at Mithapur built by reconfiguring an existing unit, “not putting fresh steel and cement on the ground.” All claimed IRRs above 16%.

The accountability moment belonged to Anand Rathi’s Nitesh Dhoot, who held management to its UK guidance — ~₹250 crore of FY26 EBITDA and positive PAT by Q3 — against an actual nine-month figure of ~₹110 crore. Mukundan conceded:

“We are behind by almost six months in the U.K. in terms of turnaround.” — R. Mukundan

The blame went partly to an uninsurable snowstorm that stopped UK salt production. Meanwhile a quiet strategic decision was disclosed: the US would deliberately shrink, refusing Southeast Asian orders at negative contribution — one final legacy shipment in Q4, then stop. HSBC’s Saurabh Jain drew out the most candid answer of the year: why don’t pre-COVID prices yield pre-COVID margins? Because fixed costs are up ~$15 million in five years, gas settled structurally higher, and coal escalates ~$5/tonne as mines age. The floor itself had moved.

May 2026 — Q4 FY26: the writedown

The year closed with the reckoning. A $208 million (₹1,837 crore) goodwill impairment on the US business, plus a ₹159 crore deferred-tax write-off; Q4 PAT before exceptionals of negative ₹279 crore; the full-year consolidated loss of ₹1,715 crore. Management was careful with the framing — only goodwill was impaired, the Wyoming mining rights (depreciated over ~100-year mine lives) stayed intact on the books — and explicit about the consequence:

“Our capex for the soda ash business is going to be only when the cycle returns and we are very clear about it.” — R. Mukundan

Two genuinely new currents ran through the call. First, supply was finally rationalizing: a 1.36-million-ton US plant mothballed, an 800,000-ton Chinese plant idled on an expired permit, Solvay trimming Spanish output — though China’s inventory still sat near 1.8 million tonnes, and Mukundan refused to call the bottom. Second, a Middle East conflict had halved imports into India (Iranian export slowdowns, Red Sea routing for Turkish cargo), pushing Indian customers toward domestic sourcing — a tailwind management called “a positive on the market front,” while conceding to Morgan Stanley that the benefit was cost-driven, not yet margin. The one risk management volunteered repeatedly: Kenya’s Magadi plant runs on heavy fuel oil from the Middle East, ~40–45 days of cover, with market rates up 50–60%.

Kotak Mutual Fund’s Arjun Khanna pushed hardest on the new projects’ economics — how does Valinokkam earn 20% IRR at twice Mithapur’s capital intensity? — and ended an unsatisfied “Maybe I’ll take this later.” The quiet bright spots: non-soda-ash revenue grew 14% to ₹6,946 crore, bicarbonate output doubled to 290,000 tonnes and is “fully sold out” (NTPC’s flue-gas cleanup is the buyer), Mithapur soda ash production hit 1 million tonnes, and the Novabay acquisition in Singapore (premium bicarb for Asian food and pharma) closed in March.

Where Things Stand

The four-quarter ledger reads: prices did not bottom when management said they had; the ₹600 crore bridge delivered roughly three-quarters; the UK turnaround ran six months late and is now promised — again — for FY27; and the US absorbed both a strategic retreat and a goodwill writedown. What held was capex discipline in direction if not in framing (the “peak is over” of July became ₹1,500 crore of NCDs by November, but every rupee aimed at India), and the India business itself, which grew volumes through every quarter of a global glut.

FY27 enters with ~₹1,300 crore of guided capex, net debt guided flat near ₹5,961 crore, and management’s own caveat that “pressure on the business is there for next year also.” The things to watch are the ones management itself listed: silica plant economics due at the Q1 FY27 call, the Kenya fuel-supply situation, whether the import-substitution tailwind converts from volume into price, and whether China’s 1.8-million-tonne inventory mountain — the number that has capped every recovery hope for three years — finally starts to shrink.

The Four Checks

1. Quality and moat. A commodity business with one genuine structural advantage: geology. Over two-thirds of capacity is natural soda ash from Wyoming trona and Lake Magadi, which is durably cheaper to produce than the synthetic route that dominates Chinese supply — and the company is the world’s third-largest producer. But a cost advantage in a commodity is a moat against bankruptcy, not against the cycle: when Chinese prices fall 56–58% in three years and inventory piles to 1.8 million tonnes, even the low-cost natural producers bleed — the US operation just absorbed a ₹1,837 crore goodwill writedown, and the company’s own admission is that the cost floor has moved up (fixed costs +$15 million in five years, structurally higher gas). The India business has a softer secondary edge — domestic scale at Mithapur, the Tata salt relationship, an import-substitution tailwind — but Tata Chemicals remains a price-taker on its core product. The remaining checks should be read with that ceiling in mind.

2. Returns on incremental capital and runway. Poor, and worsening through the cycle. ROCE has run 12% (FY23) → 8% → 4% → 3% (FY26); ROE on the fresh snapshot is 1.27%, and the three-year average is below 2%. Even the FY23 cycle peak only reached 12% — this is a business whose good years earn roughly its cost of capital and whose bad years earn almost nothing on a ₹39,000 crore balance sheet, 88% of whose segment assets sit in capital-heavy basic chemistry. The new India projects (₹515 crore salt plant, ₹775 crore silica line, ₹135 crore dense soda ash reconfiguration) claim IRRs above 16%, and the non-soda-ash portfolio grew 14% to ₹6,946 crore — a real but narrow runway. Until those claims show up in delivered returns, the record says a rupee reinvested here has earned single digits.

3. Capital allocation for the stage. Mixed, with the FY26 writedown serving as the verdict on the past and some genuine discipline visible in the present. On the debit side: the US goodwill impairment is the bill for an old overseas acquisition coming due; dividend payout ran 143% and 119% of profit in FY24–25 while borrowings climbed from ₹5,563 crore to ₹8,001 crore — dividends effectively funded by debt through a downcycle; and “peak capex is over” in July became ₹1,500 crore of NCDs for expansion by November. On the credit side: the unviable Lostock plant was shut, the US expansion was explicitly shelved “until the cycle returns,” loss-making Southeast Asian shipments were refused, and every new rupee is pointed at India at claimed >16% IRRs, including the capital-light Mithapur reconfiguration. No buyback history is visible in the data. Rational in direction now, but the cash returned to shareholders during the losses sat uneasily with the rising debt.

4. Price. As of the June 2026 snapshot, the stock trades at ₹734 — below its ₹832 book value (about 0.9x), in the lower half of its ₹580–1,027 yearly range, with a 1.49% dividend yield and a market cap of ₹18,715 crore. That looks cheap on assets, and at a cycle trough with supply finally rationalizing (a 1.36-million-ton US plant mothballed, Chinese capacity idling), there is genuine recovery option value: the group earned ₹2,434 crore as recently as FY23, against which today’s price would be under 8x. But below-book is only a bargain if the book earns; at 3% ROCE and a sub-2% three-year ROE, the discount to book is the market’s reasonable estimate that the overseas assets are worth less than their carrying value — a judgment the company itself just partially confirmed. Call it fair-to-cheap for a cyclical asset play, full for the business as it currently earns, with management’s own caveat that “pressure on the business is there for next year also.”

Sources

• Concall transcripts (4): Q1 FY26 (call Jul 25, 2025), Q2 FY26 (call Nov 3, 2025), Q3 FY26 (call Feb 2, 2026), Q4/FY26 (call May 4, 2026) — BSE filings via screener.in
• Annual reports (3): FY24, FY25, FY26 (high-signal section extracts; narrative MD&A pages were thin in the extracts, so the cycle story leans on the concalls)
• Screener snapshot: fetched 2026-06-05 (logged-out session)
• Research files: vault/Sources/Earnings/Tata Chemicals Ltd/ (digests, transcripts, snapshot — not published)